MYC and breast carcinoma: Among breast cancers classified as TNBC (309/2500)31, 57% had MYC gain or amplification (Fig. 1A and Supplemental Fig. S1A), as well as increased MYC mRNA (Fig. 1B) and decreased survival (Supplemental Fig. S1B, HR = 1.4, 95% CI: 1.0–1.9, p < 0.05).